Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
Clinical trial NCT07573215 · AVAILABLE
Trial details
- NCT number
- NCT07573215
- Sponsor
- Revolution Medicines, Inc.
- Status
- AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.